Molly Siu Ching Li

Molly Siu Ching Li

Auto-generated profile, based on publicly available information

Molly Siu Ching Li

State Key laboratory of Translational Oncology, Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2025 in Nature Reviews Clinical Oncology
Verified
Journal Article
Closed access
PDF file
JZJing Zhao
Jing Zhao
WXWanting Xu
Wanting Xu
FZFei Zhou
Fei Zhou
XZXiangyu Zhang
Xiangyu Zhang
MZMo Zhou
Mo Zhou
YXYang Xia
Yang Xia

1 August 2023 in Annals of Translational Medicine
Verified
Journal Article
Open access
PDF file
MLMolly S. C. Li
Molly S. C. Li
KMKevin K. S. Mok
Kevin K. S. Mok
TMTony S. K. Mok
Tony S. K. Mok
Review Article Developments in targeted therapy & immunotherapy—how non-small cell lung cancer management will change in the next decade: a narrative review Molly S. C. Li, Kevin K. S. Mok, Tony S. K. Mok

8 February 2023 in Cancers
Verified
Journal Article
Open access
PDF file
JCJoyce W.H. Chan
Joyce W.H. Chan
ISIvan C. H. Siu
Ivan C. H. Siu
ACAliss Tsz Ching Chang
Aliss Tsz Ching Chang
MLMolly S. C. Li
Molly S. C. Li
RLRainbow W.H. Lau
Rainbow W.H. Lau
Calvin NgCalvin Ng
Calvin Ng
The demand for parenchyma-sparing local therapies for lung cancer is rising owing to an increasing incidence of multifocal lung cancers and patients who are unfit for surgery. With the latest evidence of the efficacy of lung cancer screening, more premalignant or early-stage lung cancers are being discovered and the paradigm has shifted from treatment to prevention. Transbronchial therapy is an important armamentarium in the local treatment of lung cancers, with microwave ablation being the most promising based on early to midterm results. Adjuncts to improve transbronchial ablation efficiency and accuracy include mobile C-arm platforms, software to correct for the CT-to-body divergence, metal-containing nanoparticles, and robotic bronchoscopy. Other forms of energy including steam vapor therapy and pulse electric field are under intensive investigation.

15 February 2024 in Pathology
Verified
Journal Article
Closed access
ACAlvin Ho-Kwan Cheung
Alvin Ho-Kwan Cheung
KWKit-Yee Wong
Kit-Yee Wong
SCShuk-Ling Chau
Shuk-Ling Chau
FXFuda Xie
Fuda Xie
ZMZeta Mui
Zeta Mui
Ka Fai ToKa Fai To
Ka Fai To

2 January 2025 in Lung Cancer
Verified
Journal Article
Open access
SSStephanie Pei Li Saw
Stephanie Pei Li Saw
WZWen-Zhao Zhong
Wen-Zhao Zhong
RFRui Fu
Rui Fu
MLMolly S.C. Li
Molly S.C. Li
YGYasushi Goto
Yasushi Goto
NSNavneet Singh
Navneet Singh
The peri-operative management of non-small cell lung cancer (NSCLC) in earlier stage disease has seen significant advances in recent years with the incorporation of immune checkpoint inhibitors and targeted therapy. However, many unanswered questions and challenges remain, including the application of clinical trial data to routine clinical practice. Recognising the unique demographic profile of Asian patients with NSCLC and heterogeneous healthcare systems, the Asian Thoracic Oncology Research Group (ATORG) convened a consensus meeting in Singapore on 26 April 2024 to discuss relevant issues spanning diagnostic testing to post-neoadjuvant treatment considerations and future directions. An interdisciplinary group of 19 experts comprising medical oncologists, thoracic surgeons, radiation oncologists, pulmonologists and pathologists from Singapore, Hong Kong, Mainland China, Korea, Japan, Taiwan, India, Malaysia, Thailand, Vietnam and Australia met to discuss emerging data, identify existing gaps in clinical care and develop a multidisciplinary, multinational expert consensus statement on the peri-operative management of NSCLC tailored to the Asia-Pacific region.

1 January 2024 in Therapeutic Advances in Medical Oncology
Verified
Journal Article
Open access
MLMolly S. C. Li
Molly S. C. Li
ACAndrew L. S. Chan
Andrew L. S. Chan
KMKevin K. S. Mok
Kevin K. S. Mok
SCStephen L. Chan
Stephen L. Chan
TMTony S. K. Mok
Tony S. K. Mok
Adoption of immunotherapy has completely transformed the treatment landscape of cancer. Patients with advanced cancer treated with immunotherapy may benefit from durable tumor response and long-term survival. The most widely used immunotherapy in solid tumors is anti-programmed-death (ligand) protein (PD-(L)1), which is now an integral part of non-small cell lung cancer (NSCLC) treatment irrespective of histological cell types and tumor stage. However, the vast majority of patients with advanced NSCLC treated with anti-PD-(L)1 still develop therapeutic resistance, and the prognosis after anti-PD-(L)1 resistance is poor. Resistance mechanisms to PD-1 blockade are often complex and encompass a combination of defects within the cancer-immunity cycle. These defects include failure in antigen presentation and T-cell priming, presence of co-inhibitory immune checkpoints, inability of immune cells to infiltrate the tumor, and presence of immunosuppressive tumor microenvironment. Recently, advances in drug design, genomic sequencing, and gene editing technologies have led to development of next-generation immunotherapies that may potentially overcome these resistance mechanisms. In this review, we will discuss the anti-PD-(L)1 resistance mechanism landscape in NSCLC and four novel modalities of immunotherapy in detail, namely novel immune checkpoint inhibitor and targeted therapy combinations, bispecific antibodies, cancer vaccine, and cell therapy. These novel therapeutics have all demonstrated early clinical data in NSCLC treatment and may work synergistically with each other to restore anticancer immunity. In addition, we share our perspectives on the future promises and challenges in the transformation of these novel immunotherapies to standard clinical care.